CI

At a glance

ClinicalIndex Comparison Record
Phase 2Terminated· 52 enrolled
Drug / intervention
concurrent chemotherapy +2 moredrug
Likely dose
concurrent chemotherapy 25mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03661567
NCT03661567Phase 2Terminated
Terminated
CompareCT.gov

A Prospective, Randomized, Controlled Phase Ⅱ Study of Preventively Use of Methylprednisolone After Split-course Chemoradiotherapy to Reduce the Risk of Radiation-induced Pulmonary Injury For Bulky Local Advanced None-small Cell Lung Cancer

Sun Yat-sen University·interventional·Posted Sep 7, 2018·Updated Nov 30, 2022

In Brief

A Phase 2 clinical trial evaluating chest radiation, concurrent chemotherapy, and 1 other intervention for Non-small Cell Lung Cancer. Terminated early, enrolled 52 participants across 1 site.

Signals

Trial was terminated early

Detailed Summary

This Phase II randomized controlled study is to determine the efficacy of the preventively use of methylprednisolone after split-course chemoradiotherapy (CCRT) in locally advanced non-small cell lung cancer with bulky tumor.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesChina
Collaborators--

Timeline

Phase 2TerminatedFinished
20192020202120222023202420252026
First PostedSep 7, 2018
Enrollment StartAug 9, 2018
Primary CompletionSep 10, 2021
TodayJul 1, 2026
Enrollment to primary: 3.1 yearsPosted 7.8 years ago

Interventions

chest radiationradiation

split-course chest radiation

concurrent chemotherapydrug

weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation

Methylprednisolonedrug

Methylprednisolone after the first course of radiation, once a day, 32 milligram (mg) for 7 days, 24 mg for the next 7 days, then 16mg for 7 days, and 8 mg for the last 7 days.